US Patent

US8026279 — Crystalline form of Î³-aminobutyric acid analog

Composition of Matter · Assigned to XenoPort Inc · Expires 2026-11-10 · 0y remaining

Vulnerability score 27/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a crystalline form of a gamma-aminobutyric acid analog.

USPTO Abstract

A crystalline form of a Î³-aminobutyric acid analog, and methods of preparing same, are provided.

Drugs covered by this patent

Horizant (GABAPENTIN ENACARBIL) · Azurity

Patent Metadata

Patent number: US8026279
Jurisdiction: US
Classification: Composition of Matter
Expires: 2026-11-10
Drug substance claim: Yes
Drug product claim: Yes
Assignee: XenoPort Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.